The units comprise common stock and warrants 

Davis Polk advised the representatives of the several underwriters in connection with a $52.5 million units offering by Tenaya Therapeutics, Inc. The offering consisted of 75 million units to purchase one share of common stock and warrants. Tenaya’s common stock is listed on the Nasdaq Global Select Market under the symbol “TNYA.”

Based in South San Francisco, California, Tenaya is a clinical-stage biotechnology company focused on discovering, developing and delivering potentially curative therapies to address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: gene therapy, cellular regeneration and precision medicine.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Savannah J. Dowling and Jared Madnick. Partner David R. Bauer and associate Gabrielle Mazero provided intellectual property advice. The tax team included partner Mario J. Verdolini and associates Ted Lee and Ziyu (Jessie) Lin. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post